Pfizer CEO says fourth COVID-19 shot is necessary

A second vaccine booster shot may be necessary to protect against COVID-19.

That’s according to the head of Pfizer, which is one of three COVID-19 vaccine providers in the U.S. Pfizer’s vaccine shot requires two doses to be considered fully vaccinated against the virus, while patients are also recommended to receive a booster dose. Now, a second booster dose is recommended. 

That is because the vaccine’s effectiveness tends to wear off over time. In addition, new variants of the virus continue to pop up. In addition, Pfizer is working to develop a vaccine that will protect against all COVID-19 variants for a year.

“Many variants are coming,” Pfizer CEO Albert Bourla said during an interview with CBS. “And omicron was the first one that was able to evade in a skillful way the immune protection that we were giving. But also, in all that the duration of the protection, it doesn't last very long. So, what we are trying to do, and we are working very diligently, right now is to make not only a vaccine that will protect against all variants, including omicron, but also something that can protect for at least a year.”

Booster shots are recommended for patients five months after they receive their second vaccine dose or two months after receiving the one-shot Johnson & Johnson vaccine. Pfizer’s COVID-19 vaccine shot was fully approved by the FDA for those 16 and older in August 2021. A third dose was approved under emergency use authorization.

Pfizer intends to submit data for approval of a fourth dose soon.

“The protection that we are getting from the third, it is good enough –– actually, quite good for hospitalizations and deaths,” Bourla said. “It's not that good against infections, but it doesn't last very long. But we are just submitting those data to the FDA and then we're seeing what the experts also will say outside Pfizer.”

Find more COVID-19 news

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

California-based Acutus Medical has said its ongoing agreement to manufacture and distribute left-heart access devices for Medtronic is the company's only source of revenue. 

The scam took place over a period of seven years, resulting in Medicare being billed for more than $70 million in fraudulent claims for unnecessary scans. 

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.